Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia — Steven G. Deeks (2001) | RDL Network
Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia
Article 2001 en
Authors
SD
Steven G. Deeks
TW
Terri Wrin
TL
Teri Liegler
Abstract
1 min read
Despite the presence of reduced drug susceptibility, antiretroviral-drug therapy can provide immunologic and virologic benefit. This benefit reflects continued antiviral-drug activity and the maintenance of a viral population with a reduced replicative capacity.
Kristien Van Vaerenbergh, Thomas Harrer, Jean‐Claude Schmit, An Carbonez, Elodie Fontaine, Michael Kurowski, Mathias Grünke, Peter Löw, Astrid Rascu, Bárbara Schmidt, Matthias Schmitt, Inge Thoelen, H Walter, Kristel Van Laethem, Marc Van Ranst, Jan Desmyter, De Clercq Erik, Anne‐Mieke Vandamme
Kristien Van Vaerenbergh, Laurent Debaisieux, Nancy De Cabooter, Cathérine Declercq, K. Desmet, Katrien Fransen, Bart Maes, D. Marissens, Katherine M. Miller, Gaëtan Muyldermans, S Sprecher, Lieven Stuyver, D. Vaira, Chris Verhofstede, Georges Zissis, Marc Van Ranst, De Clercq Erik, Jan Desmyter, Anne‐Mieke Vandamme
Steven G. Deeks, Rebecca Hoh, Robert M. Grant, Terri Wrin, Jason D. Barbour, Amy Narvaez, Denise Cesar, Ken Abe, Mary Beth Hanley, Nicholas S. Hellmann, Christos J. Petropoulos, Joseph M. McCune, Marc Hellerstein
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.